| Cardiovascular Risk Management |
1 |
0.79 |
| Gout |
0 |
0.76 |
| Systemic Lupus Erythematosus |
0 |
0.57 |
| Blood |
0 |
0.52 |
| Vasculitis |
0 |
0.8 |
| Lupus |
0 |
0.7 |
| Myositis |
0 |
0.33 |
| Cardiovascular disease |
0 |
0.26 |
| Hypertension |
0 |
0.8 |
| Wisconsin |
0 |
0.26 |
| Antiphospholipid Syndrome |
0 |
0.6 |
| Arthritis |
0 |
0.2 |
| Europe |
0 |
0.2 |
| Systemic Sclerosis |
0 |
0.2 |
| Psoriatic Arthritis |
0 |
0.17 |
| Spondylitis, Spondylosis, Kyphosis |
0 |
0.16 |
| Scleroderma |
0 |
0.15 |
| Rheumatoid Arthritis |
0 |
0.6 |
| Dorsum |
0 |
0.13 |
| Lipids Management |
0 |
0.13 |
| Point-of-Care |
0 |
0.8 |
| Primary Care |
0 |
0.13 |
| Rheumatic Disease |
0 |
1 |
| Risk Management |
0 |
0.9 |
| Tobacco Cessation |
0 |
0.7 |
| Tobacco Use |
0 |
0.13 |
| Mixed Connective Tissue Disease |
0 |
0.11 |
| Connective Tissue Disease |
0 |
0.09 |
| Ankylosing Spondylitis |
0 |
0.07 |
| Aspirin |
0 |
0.07 |
| Beta Blockers |
0 |
0.07 |
| Clinical Guidelines |
0 |
0.07 |
| Diuretics |
0 |
0.07 |
| Glucocorticoid |
0 |
0.07 |
| Grant |
0 |
0.07 |
| Health Education and Counseling |
0 |
0.85 |
| Heart |
0 |
0.07 |
| Hospital |
0 |
0.07 |
| Inpatient Care |
0 |
0.07 |
| Long-Term Care |
0 |
0.07 |
| Metabolism |
0 |
0.07 |
| Tissue |
0 |
0.07 |
| Cerebrovascular Accident |
0 |
0.05 |